Can core biopsy be used instead of surgical biopsy in the diagnosis and prognostic factor analysis of breast carcinoma?

Clinical Breast Cancer

Volumn 7, Issue 10, 2007, Pages 791-795

  Ozdemir, Aysegul ^a   Voyvoda, Nuray Kadioglu ^a   Gultekin, Serap ^a   Tuncbilek, Isil ^b   Dursun, Ayse ^a   Yamac, Deniz ^a  

^a GAZI UNIVERSITY   (Turkey)

^b Ankara State Hospital   (Turkey)

Author keywords

Estrogen receptor; Hormone receptors; Progesterone receptor; Ultrasonography

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NEEDLE BIOPSY;

EID: 36049037302     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.041     Document Type: Article

References (32)

1. Osanai T, Gomi N, Wakita T, et al. Ultrasound-guided core biopsy for breast cancer: preliminary report. Jpn J Clin Oncol 2000; 30:65-67.
2. Crowe JP, Patrick RJ, Rybicki LA, et al. Does ultrasound core breast biopsy predict histologic finding on excisional biopsy? Am J Surg 2003; 186:397-399.
3. Crowe JP, Rim A, Patrick RJ, et al. A prospective review of the decline of excisional breast biopsy. Am J Surg 2002; 184:353-355.
4. Staren ED, O'Neill TP. Breast ultrasound. Surg Clin North Am 1998; 78:219-235.
5. White RR, Halperin TJ, Olson JA, et al. Impact of core-needle breast biopsy on the surgical management of mammographic abnormalities. Ann Surg 2001; 233:769-777.
6. King TA, Cederbom GJ, Champaign JL, et al. A core breast biopsy of invasive carcinoma allows for definitive surgical treatment planning. Am J Surg 1998; 176:497-501.
7. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339:974-982.
8. Caruso ML, Gabrieli G, Marzullo G, et al. Core biopsy as alternative to fine-needle aspiration biopsy in diagnosis of breast tumors. Oncologist 1998; 3:45-49.
9. Connor CS, Tawfik OW, Joyce AJ, et al. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg 2002; 184:322-324.
10. Harris GC, Denley HE, Pinder SE, et al. Correlation of histologic prognostic factors in core biopsies and therapeutic excision of invasive breast carcinoma. Am J Surg Pathol 2003; 27:11-15.
11. Monticciolo DL. Histologic grading at breast core needle biopsy: comparison with result from the excised breast specimen. Breast 2005; 11:9-14.
12. Burge CN, Chang HR, Apple SK. Do the histologic features and result of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 2006; 15:167-172.
13. Badoual C, Maruani A, Ghorra C, et al. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies- correlation with subsequent surgical excisions. Breast 2005; 14:22-27.
14. Denley H, Pinder SE, Elston CW, et al. Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 2001; 54:20-24.
15. Denley H, Ellis IO, Elston CW, et al. An audit of grading and typing of invasive breast carcinoma on needlecore biopsy specimens. J Pathol 1998; 186:ssPA10.
16. Astall EC, Bobrow LG. Assessment of the accuracy of diagnostic and prognostic information provided by core biopsy in breast carcinoma. J Pathol 1998; 186:ssPA6.
17. Sharifi S, Peterson MK, Baum JK, et al. Assessment of prognostic factors in breast core needle biopsies. Mod Pathol 1999; 12:941-945.
18. Azam M, Raju U. Correlation of histologic grading of invasive ductal carcinoma in needle core biopsies and follow-up surgical excisions [Abstract]. Am J Clin Pathol 1998; 110:517-518.
19. Berezowski K, Grimes MM, Wakely PP Jr. Correlation of histologic grading of infiltrating duct breast cancer in stereotactic core biopsies with subsequent surgical specimens [Abstract]. Mod Pathol 1997; 19:16A.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: the value of histologic grade in breast cancer and experience from a large study with long-term follow-up. Histopathology 1991; 19:403-410.
21. Fishman JE, Milikowski C, Ramsinghani R, et al. US-guided core-needle biopsy of the breast: how many specimens are necessary? Radiology 2003; 226:779-782.
22. Problems in breast pathology. In: Azzopardi JG, ed. Major Problems in Pathology. Philadelphia, PA: WB Saunders; 1989:240-257.
23. Guerra I, Algorta J, Diaz de Otazu R, et al. Immunohistochemical prognostic index for breast cancer in young women. Mol Pathol 2003; 56:323-327.
24. Blamey RW. Clinical aspects of malignant disease. In: Elston CW, Ellis IO, eds. Systemic Pathology. The Breast. 3rd ed. London: Churchill Livingstone; 1998:501-513.
25. Robertson JF, Bates K, Pearson D, et al. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 1992; 65:727-730.
26. Harris K, Morafa I, Thomas V, et al. Core biopsy is accurate in determining the hormone receptor status of early breast cancer. Am J Surg 2004; 187:567-568.
27. Douglas-Jones AG, Collett N, Morgan JM, et al. Comparison of core estrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol 2001; 54:951-955.
28. Zidan A, Christie Brown JS, Peston D, et al. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol 1997; 50:27-29.
29. Schiff R, Massarweh S, Shou J, et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9(suppl 1):447S-454S.
30. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor positive primary breast cancer. J Natl Cancer Inst 2003; 95:142-153.
31. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19:2334-2356.
32. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685.